Log in to your Inderes Free account to see all free content on this page.

C-Rad

27.60 SEK

-1.25 %

Less than 1K followers

CRAD B

NASDAQ Stockholm

Medical Equipment & Services

Health Care

Overview

Financials & Estimates

Ownership

Investor consensus

-1.25 %

-14.68 %

-13.62 %

-20.46 %

-21.14 %

-13.48 %

-24.07 %

-50.80 %

+112.56 %

C-Rad operates in the medical technology industry and focuses on the development and manufacture of systems for radiation therapy of cancer. The company's products are aimed at healthcare institutions and oncologists. The business is present on a global level, with a main presence in Europe, North America and Asia. C-Rad was founded in 2004 and is headquartered in Uppsala, Sweden.

Market cap

931.97M SEK

Turnover

471.59K SEK

Revenue

EBIT %

P/E

Dividend yield-%

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar

3.3.

2026

Extraordinary general meeting '26

6.5.

2026

Interim report Q1'26

7.5.

2026

General meeting '26

All

Webcasts

Press releases

3rd party

ShowingAll content types

C-RAD, Audiocast, Q4'25

Webcast2/12/2026, 10:00 AM

C-RAD, Audiocast, Q4'25

Regulatory press release2/12/2026, 7:00 AM

C-RAD's Year-end report Q4'25

Press release1/29/2026, 7:00 AM

Invitation to presentation of C-RAD’s year-end report and report for the fourth quarter 2025

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account

Stock market's most popular morning newsletter

Analyst comments and recommendations

Stock comparison tool

PREMIUM account

All company reports and content

Premium tools (e.g. insider transactions & stock screener)

Model portfolio

Regulatory press release1/26/2026, 1:25 PM

Tomas Blomquist appointed new CEO of C-RAD

C-RAD, Audiocast, Q3'25

Webcast10/23/2025, 9:00 AM

C-RAD, Audiocast, Q3'25

Regulatory press release10/22/2025, 3:55 PM

C-RAD has decided to repurchase own class B shares

Regulatory press release10/21/2025, 5:00 PM

C-RAD ABs Interim Report Q3 2025

Press release10/21/2025, 4:20 PM

C-RAD advances approval of interim report for Q3 2025

Regulatory press release10/21/2025, 4:15 PM

C-RAD's CEO leaves, CFO Linda Frölén appointed acting CEO, Johan Danielsson is appointed deputy CEO

Press release10/9/2025, 6:00 AM

Invitation to presentation of C-RAD’s interim report and report for the third quarter 2025

Press release9/30/2025, 7:00 AM

C-RAD Strengthens Czech Presence with a strategically important order from Krajská Nemocnice Hospital in Liberec.

Press release9/26/2025, 8:00 AM

C-RAD showcases new developments at ASTRO 2025

Regulatory press release7/28/2025, 6:00 AM

C-RAD and iRT Systems announce partnership to advance safety in radiotherapy

C-RAD, Audiocast, Q2'25

Webcast7/18/2025, 9:00 AM

C-RAD, Audiocast, Q2'25

Regulatory press release7/18/2025, 6:00 AM

C-RAD AB's Interim Report Q2 2025

Press release7/4/2025, 7:30 AM

C-RAD Secures 8 MSEK Service Order with Leading U.S. East Coast Healthcare Provider

Press release6/30/2025, 6:00 AM

Invitation to presentation of C-RAD’s interim report and report for the second quarter 2025

Press release6/26/2025, 3:30 PM

C-RAD Expands US Footprint with 10 MSEK Order to Equip Leading Texas Cancer Center with Surface Guided Radiation Therapy Solutions

Press release6/19/2025, 6:00 AM

C-RAD Signs Strategic Agreement with Leading Healthcare Provider in Germany’s Stuttgart Region Valued at 9 MSEK

Press release6/4/2025, 3:30 PM

C-RAD expands footprint in France, by joining forces with leading private healthcare provider Ramsay Santé with high-precision SGRT systems to a total value of 8.5 MSEK

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.